Loading ...
Sorry, an error occurred while loading the content.

News continued and done for now!

Expand Messages
  • Sue Adams
    Some web addresses didn t copy correctly, anything with an = or - and one just plain refused to work right, so there you will have to copy and paste in your
    Message 1 of 1 , Feb 1, 2006
    • 0 Attachment

      Some web addresses didn't copy correctly, anything with an = or - and one just plain refused to work right, so there you will have to copy and paste in your tool bar where the web address goes. Sorry for the inconvenience.


      Amarin Corporation plc Announces $26.4 Million Private Placement
      Monday December 19, 8:43 am ET

      Rick Stewart, Amarin's Chief Executive Officer, commented, "We greatly appreciate the support shown by our long term shareholders and welcome the addition of several sophisticated biotech shareholders to our investor base. This successful financing enables us to complete the US and European Huntington's disease phase III trials currently in progress with our lead product Miraxion, which are due to complete in late 2006 or early 2007. We now look forward to negotiating the partnering of a number of our other drug development programs, including Miraxion for depression, from a position of financial strength."

      Brain research wins $1 million

      One of Australia's leading neuroscience researchers has been awarded $1 million dollars to fund his ongoing cutting-edge Australian research into brain disorders.

      Dr Anthony Hannan from the Howard Florey Institute in Melbourne has won a Pfizer Australia Fellowship, believed to be Australia's largest single private medical research grant, after a gruelling independent selection process.

      There were six finalists from across the country vying for the two coveted Fellowships.

      Dr Hannan said his recent work demonstrated that environmental factors such as mental and physical exercise can delay the onset of some degenerative brain diseases such as Huntington's Disease (HD).

      Prestwick Cancels Initial Public Offering

      Firm Awaits FDA Approval of Key Drug

      By Michael S. Rosenwald
      Washington Post Staff Writer
      Thursday, December 22, 2005; Page D04

      Prestwick Pharmaceuticals Inc., a District-based drug company whose lead product is a treatment for Huntington's disease, has for the time being scrapped plans to raise $74.8 million in an initial public offering of stock.

      New compounds may prevent brain cell death

      GRANADA, Spain, Dec. 21 (UPI) -- Spanish chemists say they've developed a promising set of synthetic compounds that one day may slow or halt neurological disorders.

      The researchers at the University of Granada and colleagues based their preliminary finding on test tube studies. The compounds, particularly a synthesized metabolite of the hormone melatonin, all inhibit an enzyme called inducible nitric oxide synthase, or iNOS, which is needed to produce nitric oxide, a signaling molecule that can activate the immune system.

      Is TIERS ready?

      Questions linger as state prepares to roll out a new computer application for public assistance eligibility.

      By Corrie MacLaggan
      Thursday, December 22, 2005

      Peggy Maceo was surprised to receive a letter in October saying her sister's take-home Social Security benefits were being cut.

      The $78 monthly Medicare insurance premium, normally paid by the state, would be deducted from each monthly check of about $500, the letter said. Turns out the letter was a mistake: Nora Maceo, 50, who has a brain disorder called Huntington's disease and requires around-the-clock care at her Austin home, was one of almost 600 Texans affected by a computer problem as the state prepares to introduce a new benefits application system early next year. It was the most widespread of several problems that have affected public assistance recipients across the state during the transition.
      Other News To Note
      Amarin Corp. plc., of London, began a Phase III trial of Miraxion in Huntington's disease patients in Europe, three months after dosing began in a U.S. Phase III study. The primary endpoint is a measure of whether Miraxion taken 2 grams per day results in clinically and statistically significant changes in the Total Motor Score-4 subscale of the Unified Huntington's Disease Rating Scale. Both the randomized, double-blinded, placebo-controlled studies are being conducted under a special protocol-assessment procedure, and 240 patients are scheduled for inclusion in Europe and 300 in the U.S. Miraxion has orphan drug designation in the U.S. and in Europe.
      Please take time to read about his Father.....

      Hilgenbrinck cuts his own piece of the pie

      Sunday, December 25, 2005
      By David Adam

      Herald-Whig Staff Writer

      Living in Beverly Hills while starting to make a name for himself as an actor, Tad Hilgenbrinck now can shrug off those everyday meetings with silver screen starlets and TV superstars as no big deal.

      "The funny thing about Los Angeles is you go out and get coffee in the morning, you run into Jeff Goldblum," Hilgenbrinck said.
      This is a very touching story of children with JHD. Picture included!

      Adoptions seal family's joy

      After years of lost paperwork and other problems, David and Vera Whitlatch's adoption of three great-nieces is finalized.

      By COLLEEN JENKINS, Times Staff Writer
      Published December 25, 2005

      NEW PORT RICHEY - For years, Vera and David Whitlatch and their six daughters have considered themselves a family.

      This year, the state does, too.

      A judge in November finalized the Whitlatches' adoption of three girls, ages 6, 8 and 10, who were the daughters of David's niece. The official stamp of approval brings special meaning to this holiday season.
      Law is slow to catch up with genetics
      By Natasha Stott Despoja
      December 26, 2005
      Page 1 of 2

      Genetic testing can infringe on privacy and human rights.

      HAND in hand with the dazzling potential of genetic technology is the fear that our genetic information could be used to discriminate against us: that we could be relegated to an underclass refused employment and insurance due to an unfavourable genetic test result.

      While you may think this scenario belongs in the realm of science fiction, documented cases of genetic discrimination do exist. These include a young man with a family history of the hereditary condition, Huntington's disease, who was initially denied a job in the public service until he was able to prove he did not carry the relevant gene mutation; and the carrier of Fabry's disease, a fat storage disorder, denied life insurance despite a specialist reporting normal life expectancy, among an increasing number of cases of genetic discrimination.

      Ceasing Amniocentesis

      A noninvasive test for genetic defects in fetuses has reached human clinical studies.

      By Lauren Gravitz

      Pregnant women seeking prenatal tests for genetic defects face difficult choices. Either they accept less-than-reliable blood tests or ultrasound interpretations that leave them anxious and guessing, or they choose amniocentesis, which punctures the embryonic sac and has a small risk of causing miscarriage.

      Researchers have long envisioned the day when a test of the mother's blood or urine could conclusively detect a genetic defect in her baby. Xenomics, a New York City-based biotech firm, is now conducting the first clinical studies of a urine test that, it says, can detect Down syndrome in the fetus.

      Gold nanoparticles, radiation combo may slow Alzheimer's

      Chemists in Chile and Spain have identified a new approach for the possible treatment of Alzheimer's disease that they say has the potential to destroy beta-amyloid fibrils and plaque -- hypothesized to contribute to the mental decline of Alzheimer's patients. The researchers say the new technique, which they call a type of "molecular surgery," could halt or slow the disease's progress without harming healthy brain cells. The research is scheduled for publication in the Jan. 11 issue of the American Chemical Society's Nano Letters.
      Bristol man parked in neutral: Unusual sentencing puts truck on blocks for two years

      Published: Saturday, January 7, 2006
      By Victoria Welch
      Free Press Staff Writer

      BRISTOL -- Joe Haskins' navy blue Chevy truck sat in the driveway of his South Street apartment Friday, cleared of the recently fallen snow still blanketing other vehicles nearby.

      In his apartment, the 46-year-old Haskins lighted a cigarette and looked through the window at the vehicle. He bought the '83 model in April, he said, and worked to fix it up, stopping a persistent oil leak and making the engine purr.
      (Copy and paste this address to get it to work)

      Stem Cell Therapeutics Corp. Announces a Public Update and the Appointment of an Additional Board Member

      TSX-Venture Exchange: SSS CALGARY, Jan. 9 /CNW/ - Stem Cell Therapeutics Corp ("SCT") will bepresenting an open house public update on Friday January 20, 2006 to provide acompany overview of SCT's progress since its IPO in January of 2005. Thisreview, to be presented by Dr. Joseph Tucker, President and CEO, will discussSCT's past and current research and development efforts, as well as the Phase I clinical study in the NTx(TM)-265 stroke program. Included in thisdiscussion will be future plans to administer NTx(TM)-265 to stroke patientsin a Phase II study and overall developmental timelines will also behighlighted.http://www.newswire.ca/en/releases/archive/January2006/09/c0830.html
      Might have to copy and paste this on too.

      Putting a Rush on Identifying Genes

      By Laura van Dam

      After 10 difficult years of work, researchers announced in 1993 that they had located the gene causing Huntington's disease. Since then, the pace at which other disease-causing genes have been found has greatly accelerated, so that genes are typically located in no more than two years. Now a new tool that can reduce the time needed for a critical step involved in gene identification, from perhaps as much as 10 months to a day, should allow gene discoveries to be made much faster still.

      The tool is a map showing the approximate positions of thousands of genes-of still largely unidentified function-along the genome, the complete set of our 3 billion chemical "base pairs" of DNA. The map, which is being developed by an international consortium of 104 scientists, including researchers at the Whitehead/MIT Center for Genome Research (CGR), was made possible by a concerted previous effort that identified the chemical makeup of more than 450,000 short sections of DNA that lead to the manufacture of protein fragments. Researchers recognize that since genes direct protein production, the short sections-known as complementary DNAs, or cDNAs-are portions of genes and thus of potentially great value. But no widespread group of scientists has previously determined just what genes these DNA sections belong to.
      Amarin Reports Preliminary Results From Parkinson's Disease Pre-Clinical Program Using Miraxion
      Studies Show Miraxion Modulated Cellular Function and Demonstrated
      Neuroprotective Effects in Parkinson's Disease Models

          LONDON, January 10 /PRNewswire-FirstCall/ -- Amarin Corporation plc
      (NASDAQ: AMRN) today announced promising results from two studies in its
      pre-clinical program investigating Miraxion (ultra-pure ethyl-EPA) as a
      treatment for Parkinson's disease (PD). The pre-clinical studies were
      conducted by Cai Song, M.D., Ph.D., Associate Professor in the Department of
      Biomedical Science, University of Prince Edward Island, Canada. Dr. Song
      holds a prestigious Canada Research Chair in Psychoneuroimmunology and is a
      leading authority in the field.
      (Copy and paste address)
      DNAPrint Genomics forms personalized medicine subsidiary; geneticist to lead it


      SARASOTA -- DNAPrint Genomics Inc. has formed a new subsidiary to commercialize its personalized medicine products and hired an experienced geneticist to lead it.

      The Sarasota-based company is aiming to use its genetics testing capabilities as predictors of how well a particular therapy might work on a patient based on his or her physical makeup.

      Barbara Handelin, a board-certified medical geneticist, will serve as director of DNAPrint Pharmaceuticals Inc. She has 18 years of experience in the application of genetics to clinical medicine and drug development research.
      Avicena's HD-02 Demonstrates Potential in Treatment of Huntington's Disease
      Study Shows Compound Is Safe, Well-Tolerated and May Reduce Oxidative Injury

          PALO ALTO, Calif., Jan. 24 /PRNewswire/ -- Avicena Group, Inc., a
      developer of novel pharmaceutical and therapeutic products, announced today
      that findings from a Phase I/II study of its proprietary drug candidate for
      the treatment of Huntington's disease (HD-02) demonstrated that the drug was
      safe and well-tolerated by patients at a dose of eight grams/day.
      Additionally, patients receiving HD-02 experienced elevated serum and brain
      levels of creatine.  Results from this study, which was supported by the
      National Center for Complementary and Alternative Medicine (NIH/NCCAM), were
      published today in the journal Neurology.
      (Copy and Paste address)
      Full Story. . .

      Promising study for Avicena's Huntington's drug

      26th January 2006
      By Staff Writer

      A phase I/II study of HD-02, Avicena Group's drug candidate for the treatment of Huntington's disease, has shown that the drug was safe and well-tolerated by patients and to elevate serum and brain levels of creatine.

      Additional findings from the trial showed that serum 8-hydroxy-2'- deoxyguanosine (serum 8OH2'dG) levels, which are markedly elevated in Huntington's disease patients, were reduced for patients receiving HD-02.

      Some researchers believe that this decrease in serum 8OH2'dG may suggest reduced oxidative injury in patients with Huntington's disease.

      "We are very encouraged by the outcome of this important study. Not only did our data show that HD-02 is safe and well-tolerated, but we were also able to collect compelling evidence to indicate that the compound may reduce oxidative injury in patients with Huntington's disease," stated Dr Steven Hersch, director of the laboratory of neurodegeneration and neurotherapeutics, Massachusetts General Hospital.

      Results from this study, which was supported by the National Center for Complementary and Alternative Medicine were published in the journal Neurology.

      Full Story
      Immunosuppressor drug shows promise in fight against Huntington's disease
      Tue Jan 31, 7:34 PM ET
      A drug used to fight eczema and to combat organ rejection among transplant patients has shown promising results in lab tests against a brain disorder called Huntington's disease.
      Huntington's is caused by a flaw in a single gene, IT15, which causes a mutated form of a protein called huntingtin to proliferate, killing cells in the striatum region of the brain, a study published on Wednesday says.
      Huntington's strikes around one person in 10,000, with the problems showing up between 35 and 50.
      The initial symptoms are uncontrolled, jerky movement, leading to personality change, dementia and death, which occurs between 10 and 20 years after the first signs emerge.
      A combined team from three French medical research institutes found that a calcineurin, a protein that is plentiful in the brain, chemically modifies the rogue form of huntingtin, making it more toxic for brain cells.
      But they also found that a drug called tacrolimus inhibits the calcineurin, thus correcting levels of the huntingtin.
      So far, the tests have been carried out only on brain cells in lab dishes and on lab animals.
      The authors say, there are good hopes that the medication will also work on the same molecular pathways among humans, although only further work will bear this out.
      The study is carried in a US publication, The Journal of Neuroscience.
      The researchers are from the Curie Institute, the National Centre for Scientific Research (CNRS) and the National Institute of Health and Medical Research (Inserm). Lead authors are Frederic Saudou and Sandrine Humbert of Inserm.
      Tacrolimus, also known under and the laboratory designation of FK 506, is used to prevent rejection by liver recipients and, more recently, has begun to be prescribed, as a cream, for chronic cases of the skin disease eczema.
      "One of the most adventurous things left us is to go to bed. For no one can lay a hand on our dreams."
      E. V. Lucas
      Cure Huntington's Disease

      Your message has been successfully submitted and would be delivered to recipients shortly.
      LCT raises additional funds from US investors
      Living Cell Technologies
      January 11, 2006
      11 January 2006, Melbourne, Australia: Living Cell Technologies (ASX:LCT) announced today that it has confirmed the placement of an initial investment of $3 million through a placement of ordinary shares working with Hunter Capital International to US shareholders at A$0.205 per share. . .
      The funds raised will be used as working capital to further progress the company's NeurotrophinCell (NtCell) product towards phase I/II clinical trials. Living Cell Technologies is currently in discussions with the US Food and Drug Administration (FDA) for its lead product, NtCell – a therapy for people with Huntington's disease.
      Proteome Systems and HighQ Foundation Announce the Discovery of Prognostic and Diagnostic Markers for Neurodegenerative Disease; Two-Year Human Study Launched to Validate Markers and Enable Rapid Drug Development

      SYDNEY, Australia--(BUSINESS WIRE)--Jan. 12, 2006 - Proteome Systems (ASX:PXL) today announced an early outcome from its clinical collaboration with the HighQ Foundation in New York is the identification of multiple biomarkers for Huntington's Disease (HD) using the Proteome Systems discovery platforms.

      A 2-year human study will now validate these markers which could then be used to accelerate the development of effective new drug treatments for Huntington's Disease and other neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.
      Small step toward cure
      Scientists in field of nanotechnology have joined forces with ALS researchers in hopes of treating fatal disease
      Scientists normally think big, but researchers specializing in a fatal disease that killed baseball legend Lou Gehrig are accepting the possibility that maybe they should think small.

      Small in the scientific sense, that is.

      Yesterday, scientists in the field of nanotechnology joined ALS researchers at a meeting to attempt a unified search for treatments.
      Battling The Blues
      Ongoing research shows that omega-3 fatty acids help treat depression.
      By Patrick Perry
      Published: May/June 2005
      Several years ago, Dr. Andrew Stoll, director of the Psychopharmacology Research Laboratory at Harvard Medical School-McLean Hospital, conducted a landmark study on the role of omega-3 fatty acids in bipolar disorder and came up with some surprising results. The researcher discovered that when patients with bipolar disorder consumed omega-3 from fish oil, they experienced a marked reduction in episodes of mania and depression. Extensive research continues to demonstrate that omega-3 fatty acids form the foundation of a solid, healthy diet, while also reducing the risk of heart disease, stroke, hypertension, and arthritis, among other conditions.
      Nano World: Gold nano vs. Alzheimer's
      Gold particles only nanometers or billionths of a meter wide together with extremely weak microwaves can dissolve the abnormal protein clumps linked with Alzheimer's disease and potentially those linked with other degenerative illnesses as well, experts told UPI's Nano World.

      These findings in test-tube experiments need further validation in animals before doctors can even consider applying them as therapies for humans, cautioned lead researcher Marcelo Kogan, an organic chemist at the University of Chile in Santiago.